Some studies have used models in which the lymphoma cell line is manipulated to overexpress LN-associated chemokines such as CCL19 or CXCL13 to address the anti-tumor potential of CCR7-engineered CAR NK92 cells50 or CXCR5-engineered CAR-T cells51, respectively. The gene discussed is CCL19; the disease is neoplasm.